市場調查報告書
商品編碼
997513

重症肌無力治療藥的全球市場

Myasthenia Gravis Drugs

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球重症肌無力治療藥的市場規模,預計在分析期間(2020年∼2027年)將以8.7%的年複合成長率增長,從2020年的13億美元,到2027年達到23億美元。

本報告所分析的市場區隔之一的藥物治療部門,在分析期間中預計將以9.1%的年複合成長率增長,達到11億美元。

本報告提供全球重症肌無力治療藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • CSL Limited
  • Curavac Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Flamel Technologies S.A.
  • Galenica Ltd.
  • GlaxoSmithKline PLC
  • Grifols SA
  • Lupin Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:38公司
目錄
Product Code: MCP13519

Abstract:

Global Myasthenia Gravis Drugs Market to Reach $2.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Myasthenia Gravis Drugs estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2027, growing at a CAGR of 8.7% over the analysis period 2020-2027. Drug Treatment, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rapid Immunotherapies segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $372.1 Million, While China is Forecast to Grow at 8.2% CAGR

The Myasthenia Gravis Drugs market in the U.S. is estimated at US$372.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$391.6 Million by the year 2027 trailing a CAGR of 8.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.

Thymectomy Segment to Record 10.7% CAGR

In the global Thymectomy segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$195.8 Million in the year 2020 will reach a projected size of US$401.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$260.7 Million by the year 2027.

Select Competitors (Total 38 Featured) -

  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • CSL Limited
  • Curavac Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Flamel Technologies S.A.
  • Galenica Ltd.
  • GlaxoSmithKline PLC
  • Grifols SA
  • Lupin Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Myasthenia Gravis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Myasthenia Gravis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myasthenia Gravis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Drug Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Rapid Immunotherapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Rapid Immunotherapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Rapid Immunotherapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Thymectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Thymectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Thymectomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Myasthenia Gravis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Myasthenia Gravis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Myasthenia Gravis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Rest of Europe Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Rest of Europe 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 46: Asia-Pacific Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Asia-Pacific Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Asia-Pacific 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 49: Rest of World Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of World Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of World 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38